In this study, suppression of NO synthesis or STAT1 activation will reduce the accumulation of HIF-1α induced by doxorubicin (DOX) in cancer cells, where DOX chemotherapy can induce HIF-1α accumulation in cells and is a condition that will limit the efficacy of DOX therapy [30]. The gene discussed is HIF1A; the disease is cancer.